CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.414
EU - Europa 1.782
AS - Asia 1.576
AF - Africa 181
SA - Sud America 84
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.270
CN - Cina 748
IT - Italia 420
SG - Singapore 316
GB - Regno Unito 307
BG - Bulgaria 298
SE - Svezia 243
VN - Vietnam 179
CI - Costa d'Avorio 146
HK - Hong Kong 142
RU - Federazione Russa 132
CA - Canada 123
DE - Germania 87
FI - Finlandia 77
TR - Turchia 75
BR - Brasile 62
AT - Austria 52
JP - Giappone 38
LT - Lituania 31
IN - India 27
IE - Irlanda 26
NL - Olanda 21
MX - Messico 20
ES - Italia 18
SN - Senegal 15
FR - Francia 14
ID - Indonesia 11
CH - Svizzera 10
BJ - Benin 8
AR - Argentina 7
EG - Egitto 7
HU - Ungheria 7
PL - Polonia 7
AU - Australia 6
KR - Corea 6
PH - Filippine 6
RO - Romania 6
UA - Ucraina 5
BE - Belgio 4
BO - Bolivia 4
CO - Colombia 4
GR - Grecia 4
SA - Arabia Saudita 4
ZA - Sudafrica 4
EC - Ecuador 3
EU - Europa 3
KG - Kirghizistan 3
MY - Malesia 3
PE - Perù 3
BD - Bangladesh 2
GE - Georgia 2
IL - Israele 2
IQ - Iraq 2
IR - Iran 2
MT - Malta 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
NE - Niger 1
NO - Norvegia 1
NP - Nepal 1
RS - Serbia 1
Totale 10.048
Salva come PNG Salva come JPEG
Città #
Fairfield 838
Woodbridge 678
Santa Clara 522
Ashburn 512
Houston 476
Ann Arbor 432
Seattle 347
Chandler 307
Sofia 298
Cambridge 293
Wilmington 273
Shanghai 246
Lancaster 226
Beijing 200
New York 196
Abidjan 145
Hong Kong 142
Princeton 129
Boardman 113
Lawrence 111
Medford 107
Singapore 103
Ottawa 101
Serra 98
Des Moines 90
Nanjing 61
Dong Ket 59
Istanbul 57
London 46
San Diego 43
Florence 39
Guangzhou 39
Redwood City 34
Washington 33
Dearborn 31
Vienna 31
Phoenix 25
Milan 23
Siauliai 22
Nanchang 19
Los Angeles 18
Changsha 16
Rome 16
Dakar 15
Kunming 14
Düsseldorf 13
Jiaxing 13
Hebei 11
Shenyang 11
Chicago 10
Norwalk 10
Bremen 9
Detroit 9
Frankfurt am Main 9
Hangzhou 9
Cotonou 8
Toronto 8
Bologna 7
Fuzhou 7
Nuremberg 7
Hefei 6
Jinan 6
Kent 6
Oranmore 6
Pisa 6
Berlin 5
Cairo 5
Council Bluffs 5
Esslingen am Neckar 5
Guadalajara 5
Indiana 5
Izmir 5
Lucca 5
Mozzanica 5
Adana 4
Bareggio 4
Brussels 4
Budapest 4
Cuauhtémoc 4
Dallas 4
Empoli 4
Mexico 4
North Bergen 4
Quanzhou 4
Quezon City 4
San Francisco 4
Shenzhen 4
Surabaya 4
São Paulo 4
Tianjin 4
Bishkek 3
Bogotá 3
Buenos Aires 3
Chapel Hill 3
Chengdu 3
Edinburgh 3
Foligno 3
Fremont 3
Haikou 3
Hanoi 3
Totale 7.934
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 211
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 188
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 157
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 146
Nanomedicine in dermatology: Benefits and emerging applications 145
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 138
The Quality of Life impairment in Hidradenitis Suppurativa 132
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 128
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 128
Alexithymia affects patients with hidradenitis suppurativa 125
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 123
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 122
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 121
Optimizing acitretin use in patients with plaque psoriasis 121
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 114
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 113
Apremilast for the treatment of psoriasis 112
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 112
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 111
IL-6 as a druggable target in psoriasis: Focus on pustular variants 111
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 110
Risankizumab for the treatment of moderate to severe psoriasis 110
Acne fulminans associated with lymecycline intake: A case report 110
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 109
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 108
New insights in the pathogenesis of cutaneous autoimmune disorders. 107
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 107
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 105
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 104
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 103
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 103
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 102
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 102
Scanning the immunopathogenesis of psoriasis 102
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 102
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 101
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 101
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 101
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 101
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 100
Effective topical agents and emerging perspectives in the treatment of psoriasis. 99
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 97
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 97
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 97
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 97
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 96
New topical treatments for psoriasis 96
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 96
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 96
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 95
Biomarkers for psoriasis skin lesions 95
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 94
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 94
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 93
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 93
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 93
Granuloma annulare: A case treated with infliximab successfully 93
Tofacitinib for the treatment of moderate-to-severe psoriasis 93
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 93
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 93
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 91
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 91
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 90
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 90
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 90
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 89
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 89
IL-17 targeted therapies for psoriasis. 88
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 88
Emerging applications of nanomedicine in dermatology 87
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 87
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 86
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 85
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 85
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 85
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 85
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 83
Immunologic biomarkers for clinical and therapeutic management of psoriasis 83
Unconventional Use of Intense Pulsed Light 83
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 83
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 81
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 80
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 80
Elderly psoriatic patients under biological therapies: an Italian experience 79
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 78
Adipose tissue response to IL-17 combined with TNF-alpha exposure 78
The management of moderate-to-severe chronic plaque psoriasis 75
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 75
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 74
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 74
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 73
Psoriasis 73
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 73
European consensus statement on phenotypes of pustular psoriasis 72
Potential role of serum amyloid A in hidradenitis suppurativa 72
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 69
Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice 68
Un nuovo approccio fototerapico alle dermatosi croniche 68
Diabete mellito e malattie cutanee autoimmuni 66
Dermal CARD14 expression in psoriasis 62
Totale 9.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020540 0 0 0 0 0 0 0 0 210 150 147 33
2020/2021818 66 59 50 48 44 54 37 51 84 77 43 205
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/20251.640 6 116 28 128 366 349 233 147 267 0 0 0
Totale 10.423